(PDF) MA21.03 Heterogeneity in MET Copy Number and

MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.493

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

T. Adefila-Ideozu

Publisher

Elsevier BV

Related search

P3.01-76 Clinical Background and Response to Chemotherapy in NSCLC Patients With MET Exon14 Skipping Mutation or High MET Gene Copy Number

Journal of Thoracic Oncology

Respiratory Medicine

English

Erratum to Combination MET- And EGFR-directed Therapy in MET-overexpressing Non-Small Cell Lung Cancers: Time to Move on to Better Biomarkers?

Translational Lung Cancer Research

English

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology

Respiratory Medicine

English

MET Targeted Therapy for Lung Cancer: Clinical Development and Future Directions

Lung Cancer: Targets and Therapy

English

MET in Gastric Carcinomas: Comparison Between Protein Expression and Gene Copy Number and Impact on Clinical Outcome

British Journal of Cancer

Cancer Research

English

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

HGF and C-Met in Pathogenesis of Endometrial Carcinoma

Frontiers in Bioscience - Landmark

Molecular Biology

English

Trends in the Development of MET Inhibitors for Hepatocellular Carcinoma

Future Oncology

Cancer Research

English

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

Multidisciplinary

English